FDA Alert: Byetta, Januvia and Pancreatic Cancer

On March 14, 2013, the FDA released a Drug Safety Communication concerning Byetta, Januvia and their potential correlation with pancreatic cancer.

On March 14, 2013, the FDA released a Drug Safety Communication concerning ByettaJanuvia and others in the same class of drugs, stating:

The U.S. Food and Drug Administration (FDA) is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis, or inflammation of the pancreas, and pre-cancerous cellular changes called pancreatic duct metaplasia in patients with type 2 diabetes treated with a class of drugs called incretin mimetics.

byettaDrugs in this class work by mimicking the incretin hormones produced by the body to stimulate the release of insulin after ingesting food.  Together with exercising and eating better, these drugs can help lower blood sugar levels in adults with type 2 diabetes.

While there were previous studies suggesting these drugs may been linked to pancreatitis, this recent FDA statement raises the possibility that Byetta and Januvia may also be associated with pancreatic cancer.


Do you have a Januvia or Byetta Cancer Lawsuit?

The attorneys at Slater Slater Schulman LLP are dedicated to assisting potential plaintiffs in Januvia and Byetta cancer lawsuits. If you or someone you love have taken Byetta or Januvia and developed pancreatic and/or thyroid cancer, you should contact Slater Slater Schulman LLP for a free consultation by filling out the form on this page or by calling us at (800) 251-6990.


Leave a Reply


Anti-Spam Protection by WP-SpamFree

Follow Us on:

Contact Us

Privacy Policy

Please click here to view our privacy policy.